Nantes, France – May 23, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale) announce the presentation of four posters* on the combination of Tedopi® neo-epitopes in several cancer indications at the annual meeting of the ASCO (American Society of Clinical Oncology) to be held from June 4 to 7, 2022.
Information on poster presentations:
– Title: “A randomized non-comparative phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo), or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): first interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY” (Abstract #4148)
Presented by: Anthony TURPIN, University Hospital Center of Lille, FR
Date: Saturday, June 4, 2022
Time: 8:00 AM–11:00 AM CT